Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 DiabetesPromoter polymorphism in PCK1 (phosphoenolpyruvate carboxykinase gene) associated with type 2 diabetes mellitusMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesA comparison of ultrasound measurements to assess carotid atherosclerosis development in subjects with and without type 2 diabetes.Methylenetetrahydrofolate reductase polymorphism 677C>T is associated with peripheral arterial disease in type 2 diabetesHeart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial.Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitusImpaired fasting glucose and impaired glucose tolerance: implications for careInitial combination therapy for type 2 diabetes mellitus: is it ready for prime time?LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies.Administrative data algorithms can describe ambulatory physician utilization.Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sampleComparison of National Diabetes Data Group and American Diabetes Association diagnostic criteria for gestational diabetes in their identification of postpartum risk of glucose intolerance.Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular RiskEffect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study.Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal CanadiansChanges in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.HNF1A G319S variant, active cigarette smoking and incident type 2 diabetes in Aboriginal Canadians: a population-based epidemiological study.Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetesGlucose intolerance in pregnancy and postpartum risk of metabolic syndrome in young womenThe antepartum glucose values that predict neonatal macrosomia differ from those that predict postpartum prediabetes or diabetes: implications for the diagnostic criteria for gestational diabetesAn abnormal screening glucose challenge test in pregnancy predicts postpartum metabolic dysfunction, even when the antepartum oral glucose tolerance test is normalPre-gravid physical activity and reduced risk of glucose intolerance in pregnancy: the role of insulin sensitivity.Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study.Gestational diabetes and postpartum physical activity: evidence of lifestyle change 1 year after deliveryBeta-cell function declines within the first year postpartum in women with recent glucose intolerance in pregnancy.HNF-1alpha G319S, a transactivation-deficient mutant, is associated with altered dynamics of diabetes onset in an Oji-Cree community.Cigarette smoking and cardiovascular risk factors among Aboriginal Canadian youths.Assessing the association of the HNF1A G319S variant with C-reactive protein in Aboriginal Canadians: a population-based epidemiological study.Relationship of blood pressure to retinal vessel diameter in type 1 diabetes mellitusType 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.The diabetes control and complications trial/epidemiology of diabetes interventions and complications study: 30th anniversary presentationsRenal outcomes in patients with type 1 diabetes and macroalbuminuriaRenal and retinal effects of enalapril and losartan in type 1 diabetes
P50
Q22250887-CB128123-9221-49BF-BAE5-7ED27596876EQ24307481-B0588E74-5CBA-4761-8483-ECA103628CE7Q24642503-FFCE7175-980C-460F-A2FF-BFA98B32B31AQ24812190-A184FA9D-92A7-4B55-A403-F843F2E090B6Q24815308-505072AF-8337-47DB-81AD-24DF5DE0F7F3Q27301948-C453F708-2EB8-4664-8F8F-AB942E473344Q27311510-05A9CB97-35C1-41FB-B55A-06A2E10A7D2FQ28253541-D69B084C-8035-4A98-A800-A948F130F15CQ28290479-BD8FF3F1-5A97-44F7-8D98-DECB8AB8EB85Q30397995-1A7D2810-9FD1-4D29-88DB-3940194E1AD7Q30856973-40F2E453-8ECA-441D-BC75-42EDE38441D2Q30978576-EABD9A6E-D42B-40DA-B96E-74C88BB5EA01Q31117688-9EF0C9FB-9EFF-4BBF-90B6-672F876587E7Q33311602-42156BBC-A5D0-4939-A52D-54ED96438DDBQ33442205-E4FF83E8-3131-421D-87F6-8D43CB542321Q33556796-C06A216A-30ED-436A-9F83-7B690AF21273Q33601429-C47F0656-6FE6-47F1-92BC-1B7BDBAEF1A8Q33602286-68EFDFA1-C3A5-4DA7-B84C-6C482FCE4A0BQ33683750-A8D8C849-50C2-4BC8-84B4-580123A83DD5Q33741245-8130D390-80E1-4191-A763-6A9EEC0FA81DQ33751433-F8FF4734-7CB5-42C4-9BDD-CF09B04DC3B5Q33786252-EF3E4F58-D5B3-4FE3-95ED-CDD25B1D688CQ33812170-124D6361-4813-4D2A-BB93-C07078F8A3C0Q33835519-DEA18C6A-25FA-4699-B066-3449942A2587Q33873226-B381BE18-EAB4-471A-94F2-EC42CA07F2F8Q33879112-A31F959E-C624-41DF-AAC6-6EF3DAF08E80Q33879120-82596A28-C3A3-4DAB-97DF-D38025478F9CQ33884449-121959A5-8289-4ADB-AE33-B882E465C294Q33884471-5DD25DC0-93FF-41A1-A125-E7967422C354Q33932739-73FC0FCF-932B-4805-86D9-0B61A97BF1CFQ33948925-603C5626-C216-452E-9369-0C67CBA368A1Q34016062-1D7D7B57-7CB9-45D1-9F55-BA8FCD053164Q34049309-BCD44148-46AF-4C6A-A058-31096619955BQ34072208-FB79769B-43F3-4C08-9603-5435F818EB90Q34088086-D331F06F-6B47-4942-8793-65EB323A33BAQ34156613-4DB978FE-D65E-4963-A827-BD70808E98D1Q34219439-56B2D729-0A61-4992-B206-9466B11ACB9EQ34259401-44C42EA1-FA84-451E-ABD5-FFD203A910EBQ34260068-173ACFBE-BCBC-472B-9F3C-64DBA44B7A24Q34296719-FBB5A415-BA87-41FE-AD45-4220B37E241B
P50
description
Canadian endocrinologist
@en
name
Bernard Zinman
@ast
Bernard Zinman
@en
Bernard Zinman
@es
Bernard Zinman
@fr
Bernard Zinman
@nl
type
label
Bernard Zinman
@ast
Bernard Zinman
@en
Bernard Zinman
@es
Bernard Zinman
@fr
Bernard Zinman
@nl
prefLabel
Bernard Zinman
@ast
Bernard Zinman
@en
Bernard Zinman
@es
Bernard Zinman
@fr
Bernard Zinman
@nl
P214
P244
P21
P213
0000 0003 8523 0798
P214
P244
P31
P496
0000-0002-0041-1876
P735
P7859
lccn-n78067135